Denis Hadjiliadis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Denis Hadjiliadis has a total of 244 co-authors. Here are the top co-authors by number of shared publications:
- Shaf Keshavjee
Toronto Lung Transplant Program and Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada
5 shared publications - Jennifer L. Taylor-Cousar
Departments of Medicine and Pediatrics, National Jewish Health, Denver, CO 80206, USA
4 shared publications - Lianne G. Singer
Division of Respirology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada
4 shared publications - Raksha Jain
University of Texas Southwestern Medical Center, Dallas, TX, USA
4 shared publications - Janice Wang
Division of Pulmonary, Critical Care and Sleep Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York, NY 11042, USA
3 shared publications - Natalie E. West
Johns Hopkins University, 1830 E. Monument Street, 1830 Building 5th Floor Pulmonary, Baltimore, MD 21287, USA
3 shared publications
Latest Publications
- 27 March 2026
- Published by Elsevier in Contraception
- Vol. 161, 111454
Liver cirrhosis among females with cystic fibrosis using hormonal contraception
- 27 March 2026
- Published by Elsevier in Contraception
- Vol. 161, 111454
Liver cirrhosis among females with cystic fibrosis using hormonal contraception
- 22 January 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (3) , 491-497
Contraceptive use and pregnancy in cystic fibrosis: Survey findings from 10 cystic fibrosis centers
- 22 January 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (3) , 491-497
Contraceptive use and pregnancy in cystic fibrosis: Survey findings from 10 cystic fibrosis centers
- Open Access
- 6 December 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (2) , 224-235
Addressing pain in people living with cystic fibrosis: Cystic fibrosis foundation evidence-informed guidelines
- 6 December 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (2) , 224-235
Open AccessAddressing pain in people living with cystic fibrosis: Cystic fibrosis foundation evidence-informed guidelines
- 7 November 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (3) , 412-416
Have CFTR modulators changed the need for liver and lung transplantation among patients with cystic fibrosis? An analysis of the UNOS database
An abstract is unavailable. This article is available as a PDF only.
- 7 November 2024
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (3) , 412-416
Have CFTR modulators changed the need for liver and lung transplantation among patients with cystic fibrosis? An analysis of the UNOS database
An abstract is unavailable. This article is available as a PDF only.
- 1 July 2023
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 20 (7) , 984-992
The Clinical Association between Aspergillus fumigatus and Respiratory Outcomes in Adolescents and Adults with Cystic Fibrosis
Rationale: The clinical significance of Aspergillus fumigatus (Af) detection in the absence of allergic bronchopulmonary aspergillosis in cystic fibrosis (CF) airways remains unclear. Yet, some clinicians initiate antifungal therapy for Af-positive respiratory cultures out of concern for infection in people with CF. Objectives: To determine the association between the presence of Af and respiratory outcomes in individuals with CF. Methods: We conducted a prospective longitudinal cohort study of 206 adults and adolescents (age 14 yr and older) with CF and collected sputum for selective fungus culture. We assessed clinical outcome measurements, including patient-reported outcomes (measured by the Cystic Fibrosis Questionnaire–Revised), spirometry, and number of pulmonary exacerbations (PEx) for a 1-year period. We used mixed-effects linear models to determine the association between positive Af culture results, defined as Af detection in sputum culture at the study visit, with both respiratory domain score and forced expiratory volume in 1 second (FEV1) percent predicted, adjusted for confounders. Mixed-effects Poisson regression models were employed to examine the association between positive Af culture results and PEx events. We explored the association between Af history, defined as Af detection at baseline or within 2 years of enrollment, and respiratory outcomes. Results: Af prevalence was 10.3% (95% confidence interval [CI], 6.8, 15.7) at baseline. Forty-eight (23.3%; 95% CI, 17.7, 29.7) participants had at least one Af-positive culture result during the study period. Positive Af culture result was not associated with lower respiratory domain score. However, Af history was associated with a 6.48-point lower respiratory domain score, reflective of worse respiratory quality of life (95% CI, −11.96, −0.99; P = 0.02). Positive Af culture result was associated with a 2.54% lower FEV1 percent predicted (95% CI, −4.64, −0.44; P = 0.02) and a 1.71-fold increase in severe PEx incidence (95% CI, 1.05, 2.76; P = 0.03). Conclusions: Positive Af culture result was not associated with lower patient-reported, respiratory-related quality of life. Yet, positive Af culture result was associated with both lower FEV1 percent predicted and increased frequency of severe PEx warranting intravenous antibiotics in adolescents and adults with CF. Future studies are required to better understand the direct role of Af in lung disease progression in CF.
- 1 July 2023
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 20 (7) , 984-992
The Clinical Association between Aspergillus fumigatus and Respiratory Outcomes in Adolescents and Adults with Cystic Fibrosis
Rationale: The clinical significance of Aspergillus fumigatus (Af) detection in the absence of allergic bronchopulmonary aspergillosis in cystic fibrosis (CF) airways remains unclear. Yet, some clinicians initiate antifungal therapy for Af-positive respiratory cultures out of concern for infection in people with CF. Objectives: To determine the association between the presence of Af and respiratory outcomes in individuals with CF. Methods: We conducted a prospective longitudinal cohort study of 206 adults and adolescents (age 14 yr and older) with CF and collected sputum for selective fungus culture. We assessed clinical outcome measurements, including patient-reported outcomes (measured by the Cystic Fibrosis Questionnaire–Revised), spirometry, and number of pulmonary exacerbations (PEx) for a 1-year period. We used mixed-effects linear models to determine the association between positive Af culture results, defined as Af detection in sputum culture at the study visit, with both respiratory domain score and forced expiratory volume in 1 second (FEV1) percent predicted, adjusted for confounders. Mixed-effects Poisson regression models were employed to examine the association between positive Af culture results and PEx events. We explored the association between Af history, defined as Af detection at baseline or within 2 years of enrollment, and respiratory outcomes. Results: Af prevalence was 10.3% (95% confidence interval [CI], 6.8, 15.7) at baseline. Forty-eight (23.3%; 95% CI, 17.7, 29.7) participants had at least one Af-positive culture result during the study period. Positive Af culture result was not associated with lower respiratory domain score. However, Af history was associated with a 6.48-point lower respiratory domain score, reflective of worse respiratory quality of life (95% CI, −11.96, −0.99; P = 0.02). Positive Af culture result was associated with a 2.54% lower FEV1 percent predicted (95% CI, −4.64, −0.44; P = 0.02) and a 1.71-fold increase in severe PEx incidence (95% CI, 1.05, 2.76; P = 0.03). Conclusions: Positive Af culture result was not associated with lower patient-reported, respiratory-related quality of life. Yet, positive Af culture result was associated with both lower FEV1 percent predicted and increased frequency of severe PEx warranting intravenous antibiotics in adolescents and adults with CF. Future studies are required to better understand the direct role of Af in lung disease progression in CF.
- 5 April 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (5) , 796-803
Association between unplanned pregnancies and maternal exacerbations in cystic fibrosis
- 5 April 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (5) , 796-803
Association between unplanned pregnancies and maternal exacerbations in cystic fibrosis
- Open Access
- 15 September 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (18)
Imaging sensitive and drug-resistant bacterial infection with [11C]-trimethoprim
BACKGROUND. Several molecular imaging strategies can identify bacterial infections in humans. PET affords the potential for sensitive infection detection deep within the body. Among PET-based approaches, antibiotic-based radiotracers, which often target key bacterial-specific enzymes, have considerable promise. One question for antibiotic radiotracers is whether antimicrobial resistance (AMR) reduces specific accumulation within bacteria, diminishing the predictive value of the diagnostic test. METHODS. Using a PET radiotracer based on the antibiotic trimethoprim (TMP), [11C]-TMP, we performed in vitro uptake studies in susceptible and drug-resistant bacterial strains and whole-genome sequencing (WGS) in selected strains to identify TMP resistance mechanisms. Next, we queried the NCBI database of annotated bacterial genomes for WT and resistant dihydrofolate reductase (DHFR) genes. Finally, we initiated a first-in-human protocol of [11C]-TMP in patients infected with both TMP-sensitive and TMP-resistant organisms to demonstrate the clinical feasibility of the tool. RESULTS. We observed robust [11C]-TMP uptake in our panel of TMP-sensitive and -resistant bacteria, noting relatively variable and decreased uptake in a few strains of P. aeruginosa and E. coli. WGS showed that the vast majority of clinically relevant bacteria harbor a WT copy of DHFR, targetable by [11C]-TMP, and that despite the AMR, these strains should be “imageable.” Clinical imaging of patients with [11C]-TMP demonstrated focal radiotracer uptake in areas of infectious lesions. CONCLUSION. This work highlights an approach to imaging bacterial infection in patients, which could affect our understanding of bacterial pathogenesis as well as our ability to better diagnose infections and monitor response to therapy. TRIAL REGISTRATION. ClinicalTrials.gov NCT03424525. FUNDING. Institute for Translational Medicine and Therapeutics, Burroughs Wellcome Fund, NIH Office of the Director Early Independence Award (DP5-OD26386), and University of Pennsylvania NIH T32 Radiology Research Training Grant (5T32EB004311-12).
- 15 September 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (18)
Open AccessImaging sensitive and drug-resistant bacterial infection with [11C]-trimethoprim
BACKGROUND. Several molecular imaging strategies can identify bacterial infections in humans. PET affords the potential for sensitive infection detection deep within the body. Among PET-based approaches, antibiotic-based radiotracers, which often target key bacterial-specific enzymes, have considerable promise. One question for antibiotic radiotracers is whether antimicrobial resistance (AMR) reduces specific accumulation within bacteria, diminishing the predictive value of the diagnostic test. METHODS. Using a PET radiotracer based on the antibiotic trimethoprim (TMP), [11C]-TMP, we performed in vitro uptake studies in susceptible and drug-resistant bacterial strains and whole-genome sequencing (WGS) in selected strains to identify TMP resistance mechanisms. Next, we queried the NCBI database of annotated bacterial genomes for WT and resistant dihydrofolate reductase (DHFR) genes. Finally, we initiated a first-in-human protocol of [11C]-TMP in patients infected with both TMP-sensitive and TMP-resistant organisms to demonstrate the clinical feasibility of the tool. RESULTS. We observed robust [11C]-TMP uptake in our panel of TMP-sensitive and -resistant bacteria, noting relatively variable and decreased uptake in a few strains of P. aeruginosa and E. coli. WGS showed that the vast majority of clinically relevant bacteria harbor a WT copy of DHFR, targetable by [11C]-TMP, and that despite the AMR, these strains should be “imageable.” Clinical imaging of patients with [11C]-TMP demonstrated focal radiotracer uptake in areas of infectious lesions. CONCLUSION. This work highlights an approach to imaging bacterial infection in patients, which could affect our understanding of bacterial pathogenesis as well as our ability to better diagnose infections and monitor response to therapy. TRIAL REGISTRATION. ClinicalTrials.gov NCT03424525. FUNDING. Institute for Translational Medicine and Therapeutics, Burroughs Wellcome Fund, NIH Office of the Director Early Independence Award (DP5-OD26386), and University of Pennsylvania NIH T32 Radiology Research Training Grant (5T32EB004311-12).
- 15 April 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (3) , 383-384
A new era has dawned for persons with cystic fibrosis; however many knowledge gaps exist in our efforts to improve care
- 15 April 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (3) , 383-384
A new era has dawned for persons with cystic fibrosis; however many knowledge gaps exist in our efforts to improve care